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Comparison of long-term clinical outcome between patients with chronic versus
acute type B aortic dissection treated by implantation of a stent graft:
a single-center report
Shao Liang Chen1
1Nanjing First Hospital, Nanjing Medical University, Jiangsu, China
Background: Background: Stent grafting for treatment of type B aortic dissection has
been extensively used. However, the difference in the long-term clinical outcome
between patients with chronic versus acute type B aortic dissection remains unknown.
This study aimed to analyze the difference in long-term clinical outcome after
endovascular repair for patients with chronic ($2 weeks) versus acute (<2 weeks) type
B aortic dissection.
Methods: Between May 2000 and June 2011, a total of 174 patients with type B aortic
dissection (56 chronic, 118 acute) treated by endovascular repair were studied
prospectively. Follow-up three-dimensional computed tomography scanning and
aortoangiography were scheduled at 3–6 months after the index procedure. Propensity
score matching was used to compare the difference in the endpoint between the two
groups.
Results: The procedure-related event rate was 18.6% in the acute group and 5.4% in
the chronic group (P ¼ 0.021), but this difference became nonsigniﬁcant after
propensity score matching. At the end of follow-up (mean 2.49 years), overall and
aorta-related mortality was 11.0% and 7.6%, respectively, in the acute group, and was
not signiﬁcantly different from that in the chronic group (3.6% and 3.6%, P ¼ 0.148
and P ¼ 0.506, respectively). Both false and true lumina showed signiﬁcant remod-
eling over time, with .93% complete false-lumen thrombosis. Untreated tear and type I
endoleak were predictors of clinical events during follow-up.
Conclusions: Comparable long-term clinical results were achieved in patients with
chronic or acute type B aortic dissection after implantation of a stent graft.
TCT-742
Lower Vascular Complications With Percutaneous versus Open Transfemoral
Transcatheter Aortic Valve Replacement
Mitul B. Kadakia1, Howard C. Herrmann2, Nimesh Desai3, Zachary E. Fox1,
Jeffrey Ogbara1, Saif Anwaruddin1, Dinesh Jagasia1, Joseph E. Bavaria1,
Wilson Y. Szeto4, Prashanth Vallabhajosyula1, Rohan Menon1, Jay Giri1
1Hospital of the University of Pennsylvania, Philadelphia, PA, 2Hospital of the
University of Pennsylvania, Philadelphia, Pennsylvania, 3Penn Medicine,
Philadelphia, PA, 4University of Pennsylvania Medical Center, Philadelphia,
Pennsylvania
Background: Transcatheter aortic valve replacement (TAVR) via the transfemoral
(TF) approach is currently performed by both open surgical and percutaneous access.
Vascular complications are associated with morbidity and mortality, but few studies
have directly compared access approach.
Methods: Data was collected on all patients undergoing TF TAVR with Sapien or
Sapien XT aortic bioprostheses (Edwards Inc., Irvine, CA) between November 2007
and April 2013 at our institution. Valve Academic Research Consortium deﬁnitions
were utilized.
Results: TF TAVR was performed in 331 patients via an open surgical (n¼120) or
percutaneous (n¼211) approach. Both groups were similar in age, however the open
group had a greater incidence of cardiovascular comorbidities. The average sheath
outer diameter (OD) was slightly larger in the open group as compared to the
percutaneous group (8.6  0.4 vs. 8.4  0.6 mm, p<0.001). There were fewer major
vascular complications in the percutaneous as compared to the open group (11% vs.
20%, p¼0.03), and a trend toward fewer overall vascular complications (17% vs.
26%, p¼0.06). More patients with vascular complications in the percutaneous cohort
had minimal artery diameter (MAD) less than sheath OD (74% versus 55%, p¼0.03).
The percutaneous group had decreased length of stay (LOS) compared to the open
group (7.5  4.7 vs. 9.9  9.9 days, p¼0.003). There was no difference in in-hospital
mortality between the open and percutaneous groups (2.5 % vs. 1 %, p¼0.36). The use
of second generation TAVR sheaths and valves via a percutaneous approach was
associated with an even greater reduction in vascular complications (8% vs. 25%,B226 JACC Vol 62/18/Suppl B j October 27–Novemberp¼0.01) and LOS (7.0  4.8 versus 10.1  10.0 days, p¼0.04) as compared to the
open group with ﬁrst generation devices. Despite an increase in the difference between
sheath OD and MAD (-0.21 vs. 0.27 mm, p¼0.02) in the ﬁrst and second half of our
percutaneous access experience, the rates of vascular complications did not change
over this time.
Conclusions: TF TAVR via a percutaneous approach is associated with less vascular
morbidity and lower LOS as compared to an open surgical approach. These beneﬁts
are even greater with second-generation (Sapien XT) devices.
TCT-743
Stratiﬁcation of survival after transcatheter aortic valve replacement based on
vascular complication by VARC-1 or VARC-2 criteria
Kazuaki Okuyama1, Hasan Jilaihawi1, Mohammad Kashif1, Omar R. Sadruddin1,
Jigar Patel1, Vikas Soni1, Heera Pokhrel1, Tarun Chakravarty2, Mamoo Nakamura1,
Raj Makkar1
1Cedars-Sinai Medical Center, Los Angeles, CA, 2Cedars Sinai Medical Center, Los
Angeles, CA
Background: Valve academic research consortium (VARC) guidelines were devised
in an effort not only to standardize clinical endpoint deﬁnitions but also to select
endpoints that best reﬂect the safety and efﬁcacy of transcatheter aortic valve
replacement (TAVR). These guidelines are evolving in an expert led manner. We
sought to compare the predictive value for survival of major vascular complications
(VC) by VARC-1 and 2 deﬁnitions.
Methods: A large single center series of patients undergoing TAVR by multiple
approaches were studied. We deﬁned VC according to VARC-1 and VARC-2 deﬁ-
nition, and compared the mortality one year after the procedure. Data was analyzed
using Kaplan-Meier (KM) and Cox regression multivariable models that included all
variables related to 1-year mortality to a signiﬁcance level0.1.
Results: Data was analyzed for 388 patients. KM curves showed a numerically lower
survival rate at 1-year by major VC with both deﬁnitions, but only VARC-2 had
statistical signiﬁcance; 79.2% vs. 60.7% with VARC-2 (p ¼0.015), and 78.8% vs.
70.5% with VARC-1 (p ¼ 0.211). Cox regression multivariable model showed VC by
VARC-2 deﬁnition to be an independent predictor of 1-year mortality (p ¼ 0.004), but
not when VC was substituted by the VARC-1 deﬁnition (p¼0.08).
Conclusions: The VARC-2 deﬁnition for vascular complications offers better strati-
ﬁcation of survival than the VARC-1 deﬁnition, supporting its widespread use.
Reasons for this important difference will be discussed.TCT-744
Quantitative Assessment of Balloon-Expandable Valve Position During
Transcatheter Aortic Valve Replacement Using Intraoperative Transesophageal
Echocardiography
Leo Marcoff1, Omar K. Khalique1, Susheel Kodali1, Mathew Williams1,
Tamim Nazif1, Jean-Michel Paradis1, Isaac George1, Martin Leon2, Rebecca Hahn1
1Columbia University, New York, NY, 2Cardiovascular Research Foundation, New
York, NY
Background: Although prior studies describe the ﬂuoroscopic operator-independent
motion of the balloon-expandable valve, no studies have described the trans-
esophageal echocardiogram (TEE) appearance of valve deployment.
Methods: Intraoperative TEE from 100 consecutive* patients presenting for TAVR
were retrospectively analyzed. Patients with unreliable pacemaker capture or obvious
operator-induced device motion during deployment were excluded (n¼16). Device
position was deﬁned as the percent of total device height below the virtual annulus
(hinge points of aortic valve cusps). Device position was measured pre-deployment
(during rapid pacing) and post-deployment. Device cranial movement during
deployment was deﬁned as the difference between the pre-deployment and post-
deployment position (in mm) of the valve midpoint.1, 2013 j TCT Abstracts/POSTER/Aortic Valve Disease and Treatment
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deployment was signiﬁcantly higher than pre-deployment (16.112.5% vs.
33.712.5%, p<0.0001). Operator-independent cranial movement during deployment
was 2.41.6 mm (range -0.35 to 6.8 mm). There was foreshortening of the device
during deployment with lower edge of the valve moving farther cranially than the
upper edge (3.61.7 vs. 1.31.6 mm, p <0.0001). This movement was similar
between valve versions and vascular access. There was a trend (p ¼ 0.09) for more
movement with the 29 mm valve. Valve movement was not signiﬁcantly related to
echo parameters listed in Table 1.
Conclusions: Operator-independent cranial movement of the balloon-expandable
transcatheter valve occurs during its deployment. There is device foreshortening with
deployment explained by the fact that caudal edge of the device moves farther than the
cranial edge. This deployment movement of the device can be characterized by TEE
and may help with positioning immediately prior to valve deployment.Table 1. Transcatheter aortic valve movement during valve deployment
Device Movement
(midline), (mm) p
Valve Type
SAPIEN (n ¼ 53) 2.391.64 0.686
SAPIEN XT (n ¼ 31) 2.541.65
Valve Size (mm)
23 (n ¼ 25) 2.171.83 0.53 (23 vs.26)
0.077 (23 vs.29)
0.095 (26 vs.29)
26 (n ¼ 51) 2.431.58
29 (n ¼ 8) 3.411.02
Access
Transfemoral (TF), (n ¼
72)
2.451.65 0.87 (TF vs. TA)
0.84 (TF vs. Tao)
0.80 (TA vs. Tao)Transapical (TA), (n ¼ 8) 2.341.65
Transaortic (Tao), (n ¼
4)
2.611.72
AV Area (cm2)
<0.67 (n ¼ 41) 2.471.79 0.89
0.67 (n ¼ 43) 2.421.50
Aortic Annulus Diameter (mm)
<23 (n ¼ 38) 2.371.77 0.72
23 (n ¼ 46) 2.501.53
Interventricular septal thickness (mm)
>1.3 (n ¼ 53) 2.38 1.57 0.65
1.3 (n ¼ 31) 2.55 1.76
Valve Calciﬁcation by TEE
no/mild (n ¼ 39) 2.411.54 0.85
moderate/severe (n ¼
45)
2.471.73
Sinus Volume (cm3) by TEE
<7.6 (n ¼ 42) 2.371.70 0.68
7.6 (n ¼ 42) 2.521.58
*consecutive patients who had cardiac CT angiography as part of preoperative evaluation.TCT-745
CoreValve Oversizing Using Multislice Computed Tomography and Clinical
Outcomes: A Comparison with Transesophageal Echocardiography
Darren Mylotte1, Magdelena Dorfmeister2, Yacine Elhmidi3, Domenico Mazzitelli3,
Sabine Bleiziffer3, Rudiger Lange3, Nicolo Piazza4
1McGill University Health Center, Royal Victoria Hospital, Montreal, Quebec,
2German Heart Centre, Munich, Bavaria, 3German Heart Center Munich, Munich,
Germany, 4McGill University Health Center, Royal Victoria Hospital, Montreal,
Canada
Background: Accurate measurement of the aortic annulus and adherence to over-
sizing principles are crucial for transcatheter aortic valve replacement (TAVR). We
sought to assess adherence to transcatheter heart valve (THV) oversizing principles
according to transesophageal echocardiography (TEE) and computed tomography
(CT) and to evaluate the relationship between the adherence to oversizing and clinical
outcome.
Methods: Between 2009 and 2010, 157 aortic stenosis patients underwent screening CT
prior to CoreValve implantation. During this early experience, CT was performed only to
evaluate the peripheral vasculature. In all cases, TAVR-sizing was performed using TEE.
CT datasets were retrospectively reconstructed and the CTmean, CTarea, andCTperimeterJACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT Abstrdimensions were measured. TEE and CT diameters were used to determine oversizing.
Signiﬁcant paravalvular leak (PVL) (grade 2)was the primary clinical outcomemeasure.
Results: TEE-derived diameters were signiﬁcantly smaller than CT-based measure-
ments (p<0.0001). According to TEE and CTperimeter, 95.5% and 78.3% were
suitable for CoreValve implantation (26/29mm), respectively. Using TEE, 80.9%
received the appropriate valve size, while CTperimeter suggested that only 51.0% met
oversizing criteria. The average oversizing with TEE 20.28.3% compared to
10.18.6% with CTperimeter. After CoreValve implantation, 38 (24.2%) patients had
signiﬁcant PVL. PVL was similar among patients that satisﬁed and those that did not
satisfy sizing criteria using TEE (23.6%vs26.7%,p¼0.813). When CT data was
applied, PVL was signiﬁcantly lower in those that satisﬁed sizing criteria
(CTperimeter: 13.8%vs35.1%,p¼0.0026). Adherence to CT but not TEE-sizing, was
associated with a reduction in PVL (CTperimeter:odds ratio:0.30;95% CI:0.
13-0.65,p¼0.002). Sensitivity-speciﬁcity curves for CTperimeter identiﬁed minimal
oversizing thresholds of 9.0% and 9.6% for the 26 and 29mm CoreValves that best
predicted PVL.
Conclusions: Compared to TEE, CT-based THV-sizing yields larger annular diam-
eters, changes the selected valve size in half of all patients, and is predictive of PVL.
CTperimeter is the most sensitive CT measurement for predicting PVL.
TCT-746
Cerebral Ischemic Lesions after Percutaneous Transfemoral Aortic Valve
Implantation: Comparison between Edwards Sapien XT versus Direct Flow
Medical Valve Prosthesis
Klaudija Bijuklic1, Andreas Wandler2, Joachim Schofer3
1Medical Care Center, Hamburg, Germany, 2Medical Care Center Prof. Mathey Prof.
Schofer, Hamburg, Germany, 3Medicare center Prof Mathey, Prof Schofer, Hamburg
University Cardiovascular Center, Hamburg, Germany
Background: Objectives: To compare the cerebral embolic load, assessed by diffu-
sion weighted magnetic resonance imaging (DW-MRI), after percutaneous implan-
tation of Edwards Sapien XT (SXT) versus Direct Flow Medical aortic valve (DFM)
implantation. Background: New cerebral ischemic lesions after percutaneous
implantation of commercially available aortic valves are found in more than 80% of
patients. The DFM is a non-metallic prosthesis, which is placed pulling it through the
left ventricular outﬂow tract up to the aortic annulus, jailing the native valve behind
a polymer cuff. It is unknown whether this impacts the risk of cerebral embolization.
Methods: We performed a DW-MRI the day before and 48 to 72 h after TAVI. DW-
MRI studies were blindly analyzed by a radiologist, and all patients had a neurological
assessment before and after the procedure.
Results: In 36 consecutive patients (mean age 82.8  4.9 years, 56 % male) with
severe symptomatic aortic stenosis and high surgical risk were studied. In a SXT (16
pts), a DFM (20 pts) was successfully implanted via the femoral artery. There was no
difference in patient demographics as well as in the log EuroScore and in comor-
bidities between both groups. All pts underwent a balloon valvuloplasty before and 1
pt with SXT also after valve implantation. None of the pts had a stroke or TIA. The
incidence of new cerebral ischemic lesions did not differ signiﬁcantly in with DFM
compared to SXT pts. (17/20, 85%, versus 10/16, 62.5%, p¼0.12). However, new
ischemic lesions were more frequently found in both hemispheres in DFM compared
to SXT patients (55% vs. 18.8%, p¼0.03). The number of ischemic lesions per patient
was signiﬁcantly higher in DFM patients (3.3 2.6 for DFM vs 1.7  2.5 for SXT,
p¼0.049). For the volume of lesions there was a trend in favour of SXT (0.17 ml 0.3
cm3 vs.0.34 ml  0.56cm3, p¼0.2).
Conclusions: The type of valve prosthesis for percutaneous treatment of severe aortic
stenosis may have an impact on cerebral embolization.
TCT-747
Transcatheter Aortic Valve Replacement: Assessment of the Learning Curve
Based on the PARTNER Trial
Oluseun Alli1, Charanjit Rihal2, Rakesh Suri2, Kevin Greason2, Ron Waksman3,
Sa'ar Minha4, Rebecca Torguson5, Augusto Pichard6, Michael Mack7,
Lars Svensson8, Jeevanantham Rajeswaran9, Ashley M. Lowry9, Eugene Blackstone9,
E. Murat Tuzcu10, Vinod Thourani11, Raj Makkar12, Martin Leon13,
David Holmes Jr14
1University of Alabama at Birmingham, Birmingham, AL, 2Mayo Clinic, Rochester,
MN, 3MedStar Health Research Institute, Washington, DC, 4MedStar Washington
Hospital Center, Washington, DC, 5Washington Hospital center, washington, DC,
6washsington hospital center, Washington, United States, 7Baylor Healthcare System,
Plano, United States, 8Cleveland Clinic, Cleveland, USA, 9Cleveland Clinic,
Cleveland, OH, 10Cleveland Clinic Foundation, Cleveland, Ohio, 11Emory University,
Atlanta, GA, 12Associate Prof, UCLA school of Medicine, Los Angeles, California,
13Cardiovascular Research Foundation, New York, NY, 14Mayo Clinic College of
Medicine, Rochester, United States
Background: Transcatheter aortic-valve replacement (TAVR) is a new procedure for
the treatment of severe aortic stenosis. The number of cases require to gain proﬁciency
"learning curve" is unknown. The aim of this study is to assess the learning curve of
the team involved in the performance of TAVR in the PARTNER trial. We hypoth-
esized that a) a quantiﬁable learning curve exists for TAVR and b) process measures
of procedural proﬁciency would improve with increasing case volumesacts/POSTER/Aortic Valve Disease and Treatment B227
